H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
about
H5N1 vaccines in humansMammalian expression of virus-like particles for advanced mimicry of authentic influenza virusVirus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenzaImmunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in miceEmergence and pandemic potential of swine-origin H1N1 influenza virusClinical vaccine development for H5N1 influenza.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetExpression of avian influenza virus (H5N1) hemagglutinin and matrix protein 1 in Pichia pastoris and evaluation of their immunogenicity in mice.Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.Using plant cells as influenza vaccine substrates.Influenza vaccines based on virus-like particlesA pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice.A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models.Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin.Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus HemagglutininEgg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Animal models for the preclinical evaluation of candidate influenza vaccines.Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.Progress in developing virus-like particle influenza vaccines.Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccinesA single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferretsA novel hemagglutinin protein produced in bacteria protects chickens against H5N1 highly pathogenic avian influenza viruses by inducing H5 subtype-specific neutralizing antibodiesSuperior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus.A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferretsStockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.The influenza pandemic of 2009: lessons and implications.H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy.Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models.Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesInfluenza viruses with rearranged genomes as live-attenuated vaccines.Influenza Virus-like Particle Containing Two Different Subtypes of Hemagglutinin Confers Protection in Mice Against Lethal Challenge With A/PR8 (H1N1) and A/HK (H3N2) Viruses.A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologyProduction and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization.Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles.
P2860
Q27000896-2148BC11-2325-40EF-8128-1E8CF10C8F81Q28473294-0D2E4F1B-00D1-47B7-B498-CC4AF378CE12Q28741801-EA2C1CD3-D058-4E2E-BAE8-31364064E1B7Q28743887-6DE1EF8F-1B46-467C-9DBB-B05E4FEB63B0Q29619003-089BB909-B7D0-4968-8CB2-5CF180AFD992Q30222083-8B606ADB-3EEF-4517-BAB1-2F820D9E2235Q30227194-2FFD87FA-938A-4136-83D3-F45F76D91379Q30359355-B319EA1C-F662-485D-8D86-7E30804FA83BQ30375784-2911B23B-F7D8-4D33-8BC9-52E708D4F6EDQ30375982-90CCDC99-E3A9-4E98-9B51-D53FEF4C564AQ30375988-F0ABED85-EAD0-43B6-9B4E-CC0397525587Q30376236-867B5028-BB16-46F6-8029-F0332931F861Q30377228-2884B36E-8BEF-4FF4-B30B-A805F67C5CBFQ30377246-1E8CA6CA-A0D6-4C50-9F56-635A1308B3FAQ30379493-67A51DD6-09F3-4735-9801-B8DF5F7474E8Q30380290-FAA72DCB-9CF7-491C-ADD7-5733ABDF3F65Q30382097-4F52AD7C-99EA-4583-8030-A6FF5D4E3857Q30383623-5CEA0CDB-A402-4E11-A1AF-6AA9A24D4865Q30383973-E95F3622-4DA5-40E7-878A-07F65EF826A6Q30386640-D9AD9C94-6916-4DAE-94F6-F83DC6F568EAQ30387030-BB8E79B7-E2D5-4761-A6BE-3FEB34B7BF1DQ30389924-0B560977-3F6F-4153-B9FB-29B9505645A0Q30398811-262DC71F-D37F-4E6D-96A5-379503FB628DQ30399477-46257DFF-1C43-40ED-8D68-FB675340142AQ30399675-B9E450A1-8D85-4C96-A90C-097C8B28353EQ30402500-4B87957A-22B9-4689-B9D9-24473E100284Q30403251-28E72394-F172-4119-BBA1-3EC31A5595E4Q30406365-43916F5A-14EF-4AF5-B1EE-E1B659583BAAQ30410129-85E431E0-C1CC-4345-9BAE-76A22CF8EFDEQ30418285-372F80AD-EBAE-453D-A7EA-D41986D923B0Q30418752-48B9C007-0E02-48B0-8AFD-319C210B2E1AQ30420990-D7326C5D-A586-4892-9A17-165B8ABCA667Q30427591-5566A6CB-9F32-4C78-9935-B42232BD9AF1Q30427712-935974A0-EE3F-4B9C-8C88-34AC17300465Q30428192-CD49E337-F76D-498C-935F-330B84CEA2C2Q33474344-DAA50D6B-99FA-44EC-9CB2-F87667F9B72BQ33688229-4C127EFC-5BDF-441F-89C7-C5592F724FB4Q33865400-6729CCC3-99A1-4112-8B19-35415C1FAEBAQ33964159-224103A1-FA1C-4547-8FE9-30BBA5254828Q34288194-3A6655AD-7772-4B9C-8173-BBA1D9509CEB
P2860
H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
H5N1 VLP vaccine induced prote ...... ogenic H5N1 influenza viruses.
@ast
H5N1 VLP vaccine induced prote ...... ogenic H5N1 influenza viruses.
@en
type
label
H5N1 VLP vaccine induced prote ...... ogenic H5N1 influenza viruses.
@ast
H5N1 VLP vaccine induced prote ...... ogenic H5N1 influenza viruses.
@en
prefLabel
H5N1 VLP vaccine induced prote ...... ogenic H5N1 influenza viruses.
@ast
H5N1 VLP vaccine induced prote ...... ogenic H5N1 influenza viruses.
@en
P2093
P1433
P1476
H5N1 VLP vaccine induced prote ...... ogenic H5N1 influenza viruses.
@en
P2093
Corey J Crevar
Donald M Carter
Jenna E Achenbach
Kutubuddin Mahmood
Nutan Mytle
Penny M Heaton
Ted M Ross
P304
P356
10.1016/J.VACCINE.2008.07.084
P407
P577
2008-08-14T00:00:00Z